U
Uppthera
Pharmaceutical venture company aiming for new drug development employing 'targeted protein degradation' technology
About Uppthera
Uppthera, founded in 2023 by Nicolas Gauthier and Quentin Vassileff, operates within the digital health sector with a focus on improving therapeutic adherence for patients with chronic illnesses. Gauthier, with his background as a pharmacist and experience at companies like Bristol Myers Squibb and Sanofi, coupled with Vassileff's expertise in business development and strategy, identified a critical gap in patient care. Their shared vision led to the creation of a platform designed to support patients in managing their treatments effectively.
Read full description
The company's core offering is a digital therapeutic solution that gamifies the treatment process for individuals, particularly children, managing chronic conditions. By transforming treatment management into an engaging experience, Uppthera aims to enhance patient motivation and adherence. This solution also serves as a valuable tool for healthcare professionals and pharmaceutical companies by providing insights into treatment efficacy and patient behavior through the collection of real-world data. The platform facilitates better communication and follow-up between patients and their healthcare providers, aiming to improve overall health outcomes.
Uppthera's business model targets pharmaceutical laboratories, offering them a platform to support patients using their medications. This B2B approach generates revenue by providing pharmaceutical clients with a tool to increase the value of their treatments through improved patient adherence and data collection. The company has participated in several acceleration programs, including Wilco, Genopole, and HEC incubator at Station F, securing initial funding to support its development and pilot projects.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Incheon, South Korea
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 73.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Uppthera.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2022 | $35M | $138M | Undisclosed | — |
| SERIES A✓Equity / VC | Jul 2020 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Uppthera is 3.8K monthly website visits, up 22.6% over the last three months. Uppthera's team declined 13.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Elnora AIRewriting the rules of antiviral drug discovery |
Tallinn, Estonia | Operational | 5 | $215K | $550K |
 molab.aiLeading AI technology to create better molecules faster |
Munich, Germany | Acquired | |||
 EpsilicoGenerative AI for protein therapy design |
Berlin, Germany | Operational | |||
 Arctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics |
Reykjavík, Iceland | Operational | |||
 OmicsChartPatient-centric cancer data and analytics platform for translational cancer biologists |
Cardiff, United Kingdom | Operational | |||
 JivaAn AI platform offering a "no code" way of rapidly prototyping and productionising multimodal AI solutions |
London, United Kingdom | Operational | |||
 BionsightBionsight | Discover Novel Drug Candidates |
Chuncheon, South Korea | Operational | |||
 Mountain Valley MDInnovative biotech solutions enhancing health and agriculture through advanced delivery technologies |
Toronto, Canada | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
SBI Investment Korea
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Uppthera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Uppthera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.